ATE75483T1
(de)
|
1981-10-23 |
1992-05-15 |
Molecular Biosystems Inc |
Oligonukleotides heilmittel und dessen herstellungsverfahren.
|
DE3329892A1
(de)
|
1983-08-18 |
1985-03-07 |
Köster, Hubert, Prof. Dr., 2000 Hamburg |
Verfahren zur herstellung von oligonucleotiden
|
JP3019994B2
(ja)
|
1987-11-30 |
2000-03-15 |
ユニバーシティ オブ アイオワ リサーチ ファウンデーション |
新規なオリゴデオキシヌクレオチド、それを使用した標的遺伝子の発現をブロックする方法、及び新規なオリゴデオキシヌクレオチド並びにそれを使用した標的遺伝子の発現を阻止する方法
|
US6753423B1
(en)
|
1990-01-11 |
2004-06-22 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
|
US5914396A
(en)
|
1990-01-11 |
1999-06-22 |
Isis Pharmaceuticals, Inc. |
2'-O-modified nucleosides and phosphoramidites
|
US6395492B1
(en)
|
1990-01-11 |
2002-05-28 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
US5623065A
(en)
|
1990-08-13 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
US6005087A
(en)
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
WO1994008003A1
(en)
|
1991-06-14 |
1994-04-14 |
Isis Pharmaceuticals, Inc. |
ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
US5965722A
(en)
|
1991-05-21 |
1999-10-12 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
|
US5661134A
(en)
|
1991-10-15 |
1997-08-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
|
US6831166B2
(en)
|
1992-10-23 |
2004-12-14 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
DK1695979T3
(da)
|
1991-12-24 |
2011-10-10 |
Isis Pharmaceuticals Inc |
Gappede modificerede oligonukleotider
|
US20060270624A1
(en)
|
1991-12-24 |
2006-11-30 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
TW244371B
(ja)
|
1992-07-23 |
1995-04-01 |
Tri Clover Inc |
|
US5652355A
(en)
|
1992-07-23 |
1997-07-29 |
Worcester Foundation For Experimental Biology |
Hybrid oligonucleotide phosphorothioates
|
US6346614B1
(en)
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
DE69316369D1
(en)
|
1992-07-27 |
1998-02-19 |
Hybridon Inc |
Oligonukleotid alkylphosphonothiate
|
ES2086997T3
(es)
|
1993-01-25 |
1996-07-01 |
Hybridon Inc |
Oligonucleotido-alquilfosfonatos y -alquilfosfonotioatos.
|
US6608035B1
(en)
|
1994-10-25 |
2003-08-19 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
DK0882061T3
(da)
|
1996-02-14 |
2004-09-27 |
Isis Pharmaceuticals Inc |
Sukkermodificerede gapped oligonukleotider
|
US6015710A
(en)
|
1996-04-09 |
2000-01-18 |
The University Of Texas System |
Modulation of mammalian telomerase by peptide nucleic acids
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US5912332A
(en)
|
1996-07-26 |
1999-06-15 |
Hybridon, Inc. |
Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
|
US6794499B2
(en)
*
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
US7715989B2
(en)
|
1998-04-03 |
2010-05-11 |
Elitech Holding B.V. |
Systems and methods for predicting oligonucleotide melting temperature (TmS)
|
US6503754B1
(en)
*
|
2000-09-07 |
2003-01-07 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of BH3 interacting domain death agonist expression
|
US6210892B1
(en)
|
1998-10-07 |
2001-04-03 |
Isis Pharmaceuticals, Inc. |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
EP0999270A1
(en)
|
1998-10-09 |
2000-05-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Method of regulating SMN gene expression
|
US6465628B1
(en)
|
1999-02-04 |
2002-10-15 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of oligomeric compounds
|
US9029523B2
(en)
|
2000-04-26 |
2015-05-12 |
Ceres, Inc. |
Promoter, promoter control elements, and combinations, and uses thereof
|
US20040002153A1
(en)
|
1999-07-21 |
2004-01-01 |
Monia Brett P. |
Modulation of PTEN expression via oligomeric compounds
|
AU6492400A
(en)
*
|
1999-07-22 |
2001-02-13 |
Genaissance Pharmaceuticals, Inc. |
Drug target isogenes: polymorphisms in the prostaglandin-endoperoxide synthase 2gene
|
US6677445B1
(en)
|
1999-08-27 |
2004-01-13 |
Chiron Corporation |
Chimeric antisense oligonucleotides and cell transfecting formulations thereof
|
IL132972A0
(en)
|
1999-11-16 |
2001-03-19 |
Yissum Res Dev Co |
Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders
|
WO2001077384A2
(de)
|
2000-04-07 |
2001-10-18 |
Epigenomics Ag |
DETEKTION VON SNPs UND CYTOSIN-METHYLIERUNGEN
|
AU2001265137B2
(en)
|
2000-05-30 |
2007-06-14 |
Indiana University Research And Technology Corporation |
Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
|
US6727355B2
(en)
|
2000-08-25 |
2004-04-27 |
Jcr Pharmaceuticals Co., Ltd. |
Pharmaceutical composition for treatment of Duchenne muscular dystrophy
|
US20050054836A1
(en)
|
2000-11-09 |
2005-03-10 |
Cold Spring Harbor Laboratory |
Chimeric molecules to modulate gene expression
|
JP4303468B2
(ja)
|
2000-11-20 |
2009-07-29 |
ザ ボード オブ トラスティーズ オブ ザ ユニバーシテイ オブ イリノイ |
膜スカホールドタンパク質
|
US20040058356A1
(en)
|
2001-03-01 |
2004-03-25 |
Warren Mary E. |
Methods for global profiling gene regulatory element activity
|
US6825338B2
(en)
*
|
2001-03-30 |
2004-11-30 |
Isis Pharmaceuticals, Inc. |
Labeled oligonucleotides, methods for making same, and compounds useful therefor
|
EP1967525B1
(en)
|
2001-05-08 |
2012-11-14 |
Darwin Molecular Corporation |
A method for regulating immune function in primates using the foxp3 protein
|
US20050176025A1
(en)
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
|
AU2002344853A1
(en)
|
2001-06-14 |
2003-01-02 |
Active Pass Pharmaceuticals, Inc. |
Abca10 transporter
|
US7259150B2
(en)
|
2001-08-07 |
2007-08-21 |
Isis Pharmaceuticals, Inc. |
Modulation of apolipoprotein (a) expression
|
CA2465129A1
(en)
|
2001-10-29 |
2003-05-08 |
Mcgill University |
Acyclic linker-containing oligonucleotides and uses thereof
|
EP1472335A4
(en)
*
|
2001-11-08 |
2005-12-28 |
Univ Johns Hopkins |
METHOD AND SYSTEMS FOR NUCLEIC ACID SEQUENCING
|
US20030198983A1
(en)
|
2002-02-01 |
2003-10-23 |
Affymetrix, Inc. |
Methods of genetic analysis of human genes
|
ES2649817T3
(es)
|
2002-04-05 |
2018-01-15 |
Roche Innovation Center Copenhagen A/S |
Compuestos oligom¿¿ricos para la modulaci¿®n de la expresi¿®n de HIF-1¿Á
|
US20030228690A1
(en)
|
2002-06-10 |
2003-12-11 |
Isis Pharmaceuticals Inc. |
Antisense modulation of IL-1 receptor-associated kinase-1 expression
|
US20050130924A1
(en)
|
2002-06-26 |
2005-06-16 |
Monia Brett P. |
Antisense inhibition via RNAse H-independent reduction in mRNA
|
AU2003268032A1
(en)
|
2002-07-29 |
2004-02-16 |
Epigenesis Pharmaceuticals, Inc. |
Composition and methods for treatment and screening
|
US20050003369A1
(en)
|
2002-10-10 |
2005-01-06 |
Affymetrix, Inc. |
Method for depleting specific nucleic acids from a mixture
|
US20040219565A1
(en)
|
2002-10-21 |
2004-11-04 |
Sakari Kauppinen |
Oligonucleotides useful for detecting and analyzing nucleic acids of interest
|
AU2003291755A1
(en)
*
|
2002-11-05 |
2004-06-07 |
Isis Pharmaceuticals, Inc. |
Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
US7655785B1
(en)
|
2002-11-14 |
2010-02-02 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
|
PT2284266E
(pt)
|
2002-11-14 |
2013-12-17 |
Thermo Fisher Scient Biosciences Inc |
Siarn contra tp53
|
DK3222722T3
(da)
|
2002-11-18 |
2019-06-17 |
Roche Innovation Ct Copenhagen As |
Antisense-design
|
AU2004209599A1
(en)
|
2003-02-10 |
2004-08-19 |
Santaris Pharma A/S |
Oligomeric compounds for the modulation of ras expression
|
AU2004221760B2
(en)
|
2003-03-21 |
2010-03-18 |
Roche Innovation Center Copenhagen A/S |
Short interfering RNA (siRNA) analogues
|
FR2853663B1
(fr)
|
2003-04-14 |
2007-08-31 |
Aventis Pharma Sa |
Procede d'obtention de lignees de mastocytes a partir de tissus de porcs et procede de production de molecules de type heparine
|
WO2005001110A2
(en)
|
2003-05-29 |
2005-01-06 |
The Salk Institute For Biological Studies |
Transcriptional regulation of gene expression by small double-stranded modulatory rna
|
WO2004113867A2
(en)
|
2003-06-16 |
2004-12-29 |
University Of Massachusetts |
Exon analysis
|
CA2533701A1
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
US7888497B2
(en)
|
2003-08-13 |
2011-02-15 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
|
US20050108783A1
(en)
*
|
2003-09-23 |
2005-05-19 |
Chihiro Koike |
Porcine invariant chain protein, full length cDNA, genomic organization, and regulatory region
|
WO2005044981A2
(en)
|
2003-10-23 |
2005-05-19 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
US8188254B2
(en)
|
2003-10-30 |
2012-05-29 |
Coley Pharmaceutical Gmbh |
C-class oligonucleotide analogs with enhanced immunostimulatory potency
|
EP1756137A4
(en)
|
2003-11-05 |
2007-10-31 |
Univ Texas |
DIAGNOSTIC AND THERAPEUTIC PROCEDURES AND COMPOSITIONS CONCERNING PTEN AND BREAST CANCER
|
ES2344566T3
(es)
|
2003-12-23 |
2010-08-31 |
Santaris Pharma A/S |
Compuestos oligomericos para la modulacion de bcl-2.
|
US20050244851A1
(en)
|
2004-01-13 |
2005-11-03 |
Affymetrix, Inc. |
Methods of analysis of alternative splicing in human
|
AU2005208710A1
(en)
|
2004-01-23 |
2005-08-11 |
Avi Biopharma, Inc. |
Antisense oligomers and methods for inducing immune tolerance and immunosuppression
|
US20050164209A1
(en)
|
2004-01-23 |
2005-07-28 |
Bennett C. F. |
Hepatocyte free uptake assays
|
WO2005073378A1
(en)
|
2004-01-30 |
2005-08-11 |
Santaris Pharma A/S |
MODIFIED SHORT INTERFERING RNA (MODIFIED siRNA)
|
WO2005089169A2
(en)
|
2004-03-12 |
2005-09-29 |
Exelixis, Inc. |
Mptens as modifiers of the pten pathway and methods of use
|
US8314226B2
(en)
|
2004-03-29 |
2012-11-20 |
The General Hospital Corporation |
Oligonucleotide complex compositions and methods of use as gene alteration tools
|
US7374927B2
(en)
|
2004-05-03 |
2008-05-20 |
Affymetrix, Inc. |
Methods of analysis of degraded nucleic acid samples
|
AU2005248147A1
(en)
|
2004-05-11 |
2005-12-08 |
Alphagen Co., Ltd. |
Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
|
US7687616B1
(en)
|
2004-05-14 |
2010-03-30 |
Rosetta Genomics Ltd |
Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
|
US20050265927A1
(en)
|
2004-05-17 |
2005-12-01 |
Yale University |
Intranasal delivery of nucleic acid molecules
|
US8029985B2
(en)
|
2004-09-01 |
2011-10-04 |
Vybion, Inc. |
Amplified bioassay
|
US7838657B2
(en)
|
2004-12-03 |
2010-11-23 |
University Of Massachusetts |
Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
|
WO2006063356A1
(en)
|
2004-12-10 |
2006-06-15 |
Isis Phamaceuticals, Inc. |
Regulation of epigenetic control of gene expression
|
US7879992B2
(en)
|
2005-01-31 |
2011-02-01 |
Isis Pharmaceuticals, Inc. |
Modification of MyD88 splicing using modified oligonucleotides
|
WO2006086667A2
(en)
|
2005-02-09 |
2006-08-17 |
Avi Bio Pharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
US8999943B2
(en)
|
2005-03-14 |
2015-04-07 |
Board Of Regents, The University Of Texas System |
Antigene oligomers inhibit transcription
|
US7449297B2
(en)
|
2005-04-14 |
2008-11-11 |
Euclid Diagnostics Llc |
Methods of copying the methylation pattern of DNA during isothermal amplification and microarrays
|
US8877721B2
(en)
|
2005-04-15 |
2014-11-04 |
The Regents Of The University Of California |
Small activating RNA molecules and methods of use
|
US8586719B2
(en)
|
2005-04-27 |
2013-11-19 |
Pacific Arrow Limited |
Triterpenes for modulating gene expression and cell membrane, and as antiprotozoal agents
|
EP3308788B1
(en)
|
2005-06-23 |
2018-10-24 |
Biogen MA Inc. |
Compositions and methods for modulation of smn2 splicing
|
US8067571B2
(en)
*
|
2005-07-13 |
2011-11-29 |
Avi Biopharma, Inc. |
Antibacterial antisense oligonucleotide and method
|
WO2007031091A2
(en)
|
2005-09-15 |
2007-03-22 |
Santaris Pharma A/S |
Rna antagonist compounds for the modulation of p21 ras expression
|
WO2007086990A2
(en)
|
2005-11-17 |
2007-08-02 |
Board Of Regents, The University Of Texas System |
Modulation of gene expression by oligomers targeted to chromosomal dna
|
WO2007056829A1
(en)
|
2005-11-21 |
2007-05-24 |
Johnson & Johnson Research Pty Limited |
Multitargeting interfering rnas having two active strands and methods for their design and use
|
EP1976567B1
(en)
|
2005-12-28 |
2020-05-13 |
The Scripps Research Institute |
Natural antisense and non-coding rna transcripts as drug targets
|
US20090011004A1
(en)
|
2005-12-30 |
2009-01-08 |
Philadelphia Health & Education Corp., D/B/A/ Drexel University Of College Of Medicine |
Improved carriers for delivery of nucleic acid agents to cells and tissues
|
US8129515B2
(en)
|
2006-01-27 |
2012-03-06 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for the use in modulation of microRNAs
|
WO2007091269A2
(en)
|
2006-02-08 |
2007-08-16 |
Quark Pharmaceuticals, Inc. |
NOVEL TANDEM siRNAS
|
AU2007234191B2
(en)
|
2006-04-03 |
2012-07-12 |
Roche Innovation Center Copenhagen A/S |
Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
|
ES2362195T3
(es)
|
2006-04-07 |
2011-06-29 |
Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts |
Secuencia de mecp2 sintética para la terapia de sustitución de proteínas.
|
EP2019692B1
(en)
|
2006-05-05 |
2014-06-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of gccr
|
WO2008002996A2
(en)
|
2006-06-27 |
2008-01-03 |
Shanghai Institutes For Biological Sciences |
Rheumatoid arthritis t cell vaccine
|
US9617581B2
(en)
|
2006-08-25 |
2017-04-11 |
Duke University |
Methods for in vivo identification of endogenous mRNA targets of MicroRNAs
|
WO2008025069A1
(en)
|
2006-08-28 |
2008-03-06 |
The Walter And Eliza Hall Institute Of Medical Research |
Methods of modulating cellular activity and compositions therefor
|
WO2008029619A1
(fr)
|
2006-09-07 |
2008-03-13 |
Daiichi Sankyo Company, Limited |
Oligonucléotide antisens ena ayant une action spécifique de la séquence
|
US20080176793A1
(en)
|
2006-09-18 |
2008-07-24 |
The Regents Of The University Of California |
Upregulating activity or expression of bdnf to mitigate cognitive impairment in asymptomatic huntington's subjects
|
ES2526295T5
(es)
|
2006-10-18 |
2021-05-04 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido
|
JP2010509923A
(ja)
|
2006-11-23 |
2010-04-02 |
ミルクス セラピューティクス アンパーツゼルスカブ |
標的rnaの活性を変化させるためのオリゴヌクレオチド
|
EP2064350B1
(en)
|
2006-11-27 |
2013-01-02 |
Ludwig Institute for Cancer Research Ltd. |
Expression of foxp3 by cancer cells
|
JP5513128B2
(ja)
|
2007-01-19 |
2014-06-04 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Adrb2癌マーカー
|
WO2008103763A2
(en)
*
|
2007-02-20 |
2008-08-28 |
Sequenom, Inc. |
Methods and compositions for cancer diagnosis and treatment based on nucleic acid methylation
|
US7858592B2
(en)
|
2007-02-26 |
2010-12-28 |
The Board Of Regents Of The University Of Texas System |
Interfering RNAs against the promoter region of P53
|
US8580756B2
(en)
|
2007-03-22 |
2013-11-12 |
Santaris Pharma A/S |
Short oligomer antagonist compounds for the modulation of target mRNA
|
US8158596B2
(en)
|
2007-05-11 |
2012-04-17 |
The Regents Of The University Of Michigan |
Materials and methods for FOXP3 tumor suppression
|
US20090082297A1
(en)
|
2007-06-25 |
2009-03-26 |
Lioy Daniel T |
Compositions and Methods for Regulating Gene Expression
|
WO2009005793A2
(en)
*
|
2007-06-29 |
2009-01-08 |
Avi Biopharma, Inc. |
Tissue specific peptide conjugates and methods
|
WO2009027349A2
(en)
|
2007-08-24 |
2009-03-05 |
Oryzon Genomics Sa |
Treatment and prevention of neurodegenerative diseases
|
EP2623598B1
(en)
|
2007-10-04 |
2018-08-01 |
Roche Innovation Center Copenhagen A/S |
Micromirs
|
EP2205746A4
(en)
|
2007-10-04 |
2010-12-22 |
Univ Texas |
MODULATION OF GENE EXPRESSION WITH AGRNA AND GAPS WITH ANTISENSE TRANSCRIPTS AS A TARGET
|
ITRM20070523A1
(it)
*
|
2007-10-05 |
2009-04-06 |
Consiglio Nazionale Ricerche |
Acido nucleico codificante per una proteina regolatrice specifica della trascrizione dell'utrofina proteina da esso codificata e sue applicazioni
|
KR20100105550A
(ko)
|
2007-11-09 |
2010-09-29 |
아이시스 파마수티컬즈 인코포레이티드 |
7 인자 발현 조절
|
US8937217B2
(en)
|
2007-12-18 |
2015-01-20 |
E. I. Du Pont De Nemours And Company |
Down-regulation of gene expression using artificial microRNAs
|
WO2009090182A1
(en)
|
2008-01-14 |
2009-07-23 |
Santaris Pharma A/S |
C4'-substituted - dna nucleotide gapmer oligonucleotides
|
US8361980B2
(en)
|
2008-03-07 |
2013-01-29 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microRNA related diseases
|
US8703929B2
(en)
|
2008-03-07 |
2014-04-22 |
Senesco Technologies, Inc. |
Compositions comprising siRNA and plasmids
|
EP2274423A2
(en)
|
2008-04-04 |
2011-01-19 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
WO2009124341A1
(en)
|
2008-04-07 |
2009-10-15 |
The University Of Queensland |
Rna molecules and uses thereof
|
WO2009134710A2
(en)
*
|
2008-04-28 |
2009-11-05 |
The Trustees Of The University Of Pennsylvania |
Methods for enhancing utrophin production via inhibition of microrna
|
WO2009151546A2
(en)
|
2008-05-27 |
2009-12-17 |
Ptc Therapeutics, Inc. |
Methods for treating spinal muscular atrophy
|
US8222221B2
(en)
|
2008-06-04 |
2012-07-17 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression through endogenous small RNA targeting of gene promoters
|
CA2635187A1
(en)
|
2008-06-05 |
2009-12-05 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Oligonucleotide duplexes and uses thereof
|
DK2310505T3
(en)
|
2008-06-30 |
2017-10-16 |
Roche Innovation Ct Copenhagen As |
ANTIDOT oligomers
|
EP2317847B1
(en)
|
2008-07-29 |
2019-04-17 |
The Board of Regents of The University of Texas System |
Selective inhibition of polyglutamine protein expression
|
US20110237606A1
(en)
|
2008-09-26 |
2011-09-29 |
Agency Of Science, Technology And Research |
3-Deazaneplanocin Derivatives
|
CN102239260B
(zh)
|
2008-10-03 |
2017-04-12 |
库尔纳公司 |
通过抑制针对载脂蛋白‑a1的天然反义转录物治疗载脂蛋白‑a1相关疾病
|
JP2012505913A
(ja)
|
2008-10-16 |
2012-03-08 |
マリーナ バイオテック,インコーポレイテッド |
遺伝子発現を抑制する治療におけるリポソームによる効率的な送達のプロセスおよび組成物
|
JP2012508569A
(ja)
|
2008-11-17 |
2012-04-12 |
エフ.ホフマン−ラ ロシュ アーゲー |
第vii因子遺伝子の発現を阻害するための組成物および方法
|
GB0821457D0
(en)
|
2008-11-24 |
2008-12-31 |
Trillion Genomics Ltd |
Oligonucleotides
|
JP6091752B2
(ja)
|
2008-12-04 |
2017-03-08 |
クルナ・インコーポレーテッド |
Epoに対する天然アンチセンス転写物の抑制によるエリスロポエチン(epo)関連疾患の治療
|
CN107338251A
(zh)
|
2008-12-04 |
2017-11-10 |
库尔纳公司 |
通过抑制肿瘤抑制基因的天然反义转录物治疗肿瘤抑制基因相关性疾病
|
CN108042560A
(zh)
|
2008-12-04 |
2018-05-18 |
库尔纳公司 |
通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1相关的疾病
|
EP2370581B1
(en)
|
2008-12-04 |
2016-08-03 |
CuRNA, Inc. |
Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
|
US9023820B2
(en)
|
2009-01-26 |
2015-05-05 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein C-III expression
|
EP2396408B1
(en)
|
2009-02-12 |
2017-09-20 |
CuRNA, Inc. |
Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
|
HUE026280T2
(en)
|
2009-02-12 |
2016-06-28 |
Curna Inc |
Treatment of brain-derived neurotrophic factor (BDNF) -related diseases by inhibition of natural antisense transcripts associated with BDNF \ t
|
WO2010093860A2
(en)
|
2009-02-13 |
2010-08-19 |
The General Hospital Corporation |
Isolation of factors that associate directly or indirectly with chromatin
|
EP2963116B1
(en)
|
2009-03-04 |
2020-11-11 |
CuRNA, Inc. |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
|
JP6116242B2
(ja)
|
2009-03-16 |
2017-04-19 |
クルナ・インコーポレーテッド |
核因子(赤血球由来2)様2(nrf2)に対する天然アンチセンス転写物の抑制によるnrf2関連疾患の治療
|
JP5904935B2
(ja)
|
2009-03-17 |
2016-04-20 |
クルナ・インコーポレーテッド |
デルタ様1ホモログ(dlk1)に対する天然アンチセンス転写物の抑制によるdlk1関連疾患の治療
|
DK2424987T3
(en)
|
2009-05-01 |
2018-02-26 |
Curna Inc |
TREATMENT OF HEMOGLOBIN (HBF / HBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO HBF / HBG
|
CN103223177B
(zh)
|
2009-05-06 |
2016-08-10 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
WO2010129746A2
(en)
|
2009-05-06 |
2010-11-11 |
Curna, Inc. |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
CA3185821A1
(en)
|
2009-05-08 |
2010-11-11 |
Curna, Inc. |
Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
|
EP2432881B1
(en)
|
2009-05-18 |
2017-11-15 |
CuRNA, Inc. |
Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
|
KR101703695B1
(ko)
|
2009-05-22 |
2017-02-08 |
큐알엔에이, 인크. |
전사 인자 e3(tfe3)에 대한 천연 안티센스 전사체의 억제에 의해 tfe3 및 인슐린 수용체 기질 2(irs2)의 치료
|
KR20120024819A
(ko)
|
2009-05-28 |
2012-03-14 |
오피케이오 큐알엔에이, 엘엘씨 |
항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 트리스테트라프롤린 관련된 질환의 치료
|
KR101702689B1
(ko)
|
2009-06-16 |
2017-02-06 |
큐알엔에이, 인크. |
Pon1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(pon1) 관련된 질환의 치료
|
ES2620960T3
(es)
|
2009-06-16 |
2017-06-30 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con un gen de colágeno mediante la inhibición de un transcrito antisentido natural a un gen de colágeno
|
CA2765889A1
(en)
|
2009-06-24 |
2010-12-29 |
Opko Curna, Llc |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
KR101807324B1
(ko)
|
2009-06-26 |
2017-12-08 |
큐알엔에이, 인크. |
다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료
|
CA2768598A1
(en)
|
2009-07-22 |
2011-01-27 |
Cenix Bioscience Gmbh |
Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
|
EP2458005A1
(en)
|
2009-07-23 |
2012-05-30 |
Galaxy Pharma Inc. |
Fgf21 cis-element binding substance
|
US20120252869A1
(en)
|
2009-07-24 |
2012-10-04 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
ES2585360T3
(es)
|
2009-08-05 |
2016-10-05 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con un gen de la insulina (INS) por inhibición de la transcripción antisentido natural en un gen de la insulina (INS)
|
KR101827015B1
(ko)
|
2009-08-11 |
2018-02-07 |
큐알엔에이, 인크. |
아디포넥틴(adipoq)에 대한 천연 안티센스 전사체의 억제에 의한 아디포넥틴(adipoq) 관련된 질환의 치료
|
CN102482670B
(zh)
|
2009-08-21 |
2018-06-15 |
库尔纳公司 |
通过抑制‘hsp70-相互作用蛋白的c末端’(chip)的天然反义转录物而治疗chip相关疾病
|
WO2011031482A2
(en)
|
2009-08-25 |
2011-03-17 |
Curna, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
WO2011025862A2
(en)
|
2009-08-28 |
2011-03-03 |
Curna, Inc. |
Treatment of atp-binding cassette sub-family b member 1 (abcb1) related diseases by inhibition of natural antisense transcript to abcb1
|
WO2011032109A1
(en)
|
2009-09-11 |
2011-03-17 |
Sma Foundation |
Biomarkers for spinal muscular atrophy
|
WO2011038205A2
(en)
|
2009-09-25 |
2011-03-31 |
Curna, Inc. |
Treatment of growth hormone (gh) related diseases by inhibition of natural antisense transcript to gh
|
US20120295952A1
(en)
|
2009-09-25 |
2012-11-22 |
Curna, Inc. |
Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
|
WO2011048125A1
(en)
|
2009-10-20 |
2011-04-28 |
Santaris Pharma A/S |
Oral delivery of therapeutically effective lna oligonucleotides
|
KR101138048B1
(ko)
|
2009-11-06 |
2012-04-23 |
성균관대학교산학협력단 |
Bdnf의 발현을 증가시키는 신규 펩타이드 및 이를 포함하는 알츠하이머병 또는 파킨슨병의 예방 및 치료용 약학 조성물
|
JP6025567B2
(ja)
|
2009-12-16 |
2016-11-16 |
カッパーアールエヌエー,インコーポレイテッド |
膜結合転写因子ペプチダーゼ、部位1(mbtps1)に対する天然アンチセンス転写物の阻害によるmbtps1関連性疾患の治療
|
RU2619185C2
(ru)
|
2009-12-23 |
2017-05-12 |
Курна, Инк. |
Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2
|
WO2011079261A2
(en)
|
2009-12-23 |
2011-06-30 |
Curna, Inc. |
Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
|
JP5982288B2
(ja)
|
2009-12-29 |
2016-08-31 |
カッパーアールエヌエー,インコーポレイテッド |
腫瘍タンパク質63(p63)に対する天然アンチセンス転写物の阻害による腫瘍タンパク質63関連疾患の治療
|
CA2785173A1
(en)
|
2009-12-29 |
2011-07-28 |
Curna, Inc. |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
ES2677044T3
(es)
|
2009-12-31 |
2018-07-27 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el sustrato 2 del receptor de insulina (IRS2) mediante inhibición de transcrito antisentido natural para el IRS2 y factor de transcripción E3 (TFE3)
|
NO2521784T3
(ja)
|
2010-01-04 |
2018-05-05 |
|
|
RU2612161C2
(ru)
|
2010-01-06 |
2017-03-02 |
Курна, Инк. |
Лечение заболеваний, связанных с геном развития поджелудочной железы, путем ингибирования природного антисмыслового транскрипта к гену развития поджелудочной железы
|
ES2664866T3
(es)
|
2010-01-11 |
2018-04-23 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg
|
CN102782135A
(zh)
|
2010-01-25 |
2012-11-14 |
库尔纳公司 |
通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病
|
US9574191B2
(en)
|
2010-02-03 |
2017-02-21 |
The Board Of Regents Of The University Of Texas System |
Selective inhibition of polyglutamine protein expression
|
EP2536738A4
(en)
|
2010-02-08 |
2014-09-17 |
Isis Pharmaceuticals Inc |
METHODS AND COMPOSITIONS SUITABLE FOR THE TREATMENT OF CONDITIONS OR CONDITIONS IN RELATION TO THE EXPANSION OF REPETITIONS
|
WO2011097582A2
(en)
|
2010-02-08 |
2011-08-11 |
Opko Curna Llc |
Treatment of arachidonate 12-lipoxygenase, 12r type (alox12b) related diseases by inhibition of natural antisense transcript to alox12b
|
KR101838308B1
(ko)
|
2010-02-22 |
2018-03-13 |
큐알엔에이, 인크. |
피롤린-5-카르복실레이트 환원효소 1(pycr1)에 대한 천연 안티센스 전사체의 억제에 의한 pycr1과 관련된 질환의 치료
|
WO2011117353A1
(en)
|
2010-03-24 |
2011-09-29 |
Mirrx Therapeutics A/S |
Bivalent antisense oligonucleotides
|
CA2795145C
(en)
|
2010-04-02 |
2019-01-22 |
Curna, Inc. |
Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
|
EP3517613A1
(en)
|
2010-04-09 |
2019-07-31 |
CuRNA, Inc. |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
EP2558578B1
(en)
|
2010-04-13 |
2015-10-28 |
Life Technologies Corporation |
Compositions and methods for inhibition of nucleic acids function
|
US9089588B2
(en)
|
2010-05-03 |
2015-07-28 |
Curna, Inc. |
Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT)
|
TWI586356B
(zh)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
WO2011146675A2
(en)
|
2010-05-19 |
2011-11-24 |
Opko Curna Llc |
Treatment of lim homeobox 2 (lhx2) related diseases by inhibition of natural antisense transcript to lhx2
|
AR081209A1
(es)
|
2010-05-19 |
2012-07-04 |
Opko Curna Llc |
Tratamiento de enfermedades relacionadas con la proteina 11 del tipo linfoma 2 de celulas b, (bcl2, bcl2l11) mediante la inhibicion del transcripto antisentido natural a bcl2l11
|
EP2576784B1
(en)
|
2010-05-26 |
2017-11-15 |
CuRNA, Inc. |
Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
|
EP2576783B1
(en)
|
2010-05-26 |
2017-11-29 |
CuRNA, Inc. |
Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
|
WO2011159836A2
(en)
|
2010-06-15 |
2011-12-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating interaction between proteins and target nucleic acids
|
US20120004278A1
(en)
|
2010-06-18 |
2012-01-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Linc rnas in cancer diagnosis and treatment
|
GB201010557D0
(en)
|
2010-06-23 |
2010-08-11 |
Mina Therapeutics Ltd |
RNA molecules and uses thereof
|
PT2585596T
(pt)
|
2010-06-23 |
2021-03-23 |
Curna Inc |
Tratamento de doenças relacionadas com a subunidade alfa de canais de sódio dependentes de voltagem (scna) por inibição da transcrição antissentido natural para scna
|
US20130122046A1
(en)
|
2010-07-09 |
2013-05-16 |
Institut Pasteur Of Shanghai, Cas |
Regulatory factor of foxp3 and regulatory t cells and use thereof
|
TW201209163A
(en)
|
2010-07-12 |
2012-03-01 |
Opko Curna Llc |
Treatment of BCL2 binding component 3 (BBC3) related diseases by inhibition of natural antisense transcript to BBC3
|
NO2593547T3
(ja)
|
2010-07-14 |
2018-04-14 |
|
|
WO2012012443A2
(en)
|
2010-07-19 |
2012-01-26 |
Bennett C Frank |
Modulation of dystrophia myotonica-protein kinase (dmpk) expression
|
WO2012018881A2
(en)
|
2010-08-03 |
2012-02-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for the regulation of rna
|
WO2012024478A2
(en)
|
2010-08-19 |
2012-02-23 |
Opko Curna Llc |
Treatment of nicotinamide phosphoribosyltransferase (nampt) related diseases by inhibition of natural antisense transcript to nampt
|
PL2614369T3
(pl)
|
2010-09-10 |
2016-08-31 |
Epizyme Inc |
Sposób określania przydatności inhibitorów ludzkiego ezh2 w leczeniu
|
WO2012047956A2
(en)
|
2010-10-06 |
2012-04-12 |
Opko Curna Llc |
Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
|
CN103180445B
(zh)
|
2010-10-22 |
2018-02-16 |
库尔纳公司 |
通过抑制α‑L‑艾杜糖醛酸酶(IDUA)的天然反义转录物而治疗IDUA相关疾病
|
CN103201387B
(zh)
|
2010-10-27 |
2018-02-02 |
库尔纳公司 |
通过抑制干扰素相关发育调节因子1(ifrd1)的天然反义转录物而治疗ifrd1相关疾病
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
EP3260540A1
(en)
|
2010-11-12 |
2017-12-27 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
US10000752B2
(en)
|
2010-11-18 |
2018-06-19 |
Curna, Inc. |
Antagonat compositions and methods of use
|
JP6071893B2
(ja)
|
2010-11-23 |
2017-02-01 |
カッパーアールエヌエー,インコーポレイテッド |
Nanogへの天然アンチセンス転写物の阻害によるnanog関連疾患の治療
|
EP2655621B1
(en)
|
2010-12-20 |
2018-05-23 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
US9206479B2
(en)
|
2011-02-09 |
2015-12-08 |
University Of Rochester |
Methods and compositions related to Staufen 1 binding sites formed by duplexing Alu elements
|
WO2012144220A1
(en)
|
2011-04-22 |
2012-10-26 |
Oncotherapy Science, Inc. |
Ezh2 as target gene for cancer therapy and diagnosis
|
US8557787B2
(en)
|
2011-05-13 |
2013-10-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine
|
CN103620036B
(zh)
|
2011-06-09 |
2016-12-21 |
库尔纳公司 |
通过抑制共济蛋白(fxn)的天然反义转录物而治疗fxn 相关疾病
|
EP2729605B1
(en)
|
2011-07-05 |
2017-02-08 |
The General Hospital Corporation |
Rna-yy1 interactions
|
CN108272782B
(zh)
|
2011-09-06 |
2021-04-23 |
库尔纳公司 |
小分子在制备治疗Dravet综合征或全面性癫痫伴热性惊厥附加症的药物中的用途
|
WO2013040429A1
(en)
|
2011-09-14 |
2013-03-21 |
Rana Therapeutics Inc. |
Multimeric oligonucleotide compounds
|
ITMI20120275A1
(it)
|
2012-02-24 |
2013-08-25 |
Biogenera Societa A Responsabilita Limitata |
Oligonucleotidi per la modulazione dell'espressione genica e loro usi
|
ES2694592T3
(es)
|
2012-03-15 |
2018-12-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF
|
JP2016528873A
(ja)
|
2012-05-16 |
2016-09-23 |
ラナ セラピューティクス インコーポレイテッド |
遺伝子発現を調節するための組成物及び方法
|
US20150141320A1
(en)
|
2012-05-16 |
2015-05-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating gene expression
|
JP2015518711A
(ja)
|
2012-05-16 |
2015-07-06 |
ラナ セラピューティクス インコーポレイテッド |
Bdnf発現を調節するための組成物及び方法
|
JP2015523855A
(ja)
|
2012-05-16 |
2015-08-20 |
ラナ セラピューティクス インコーポレイテッド |
Apoa1及びabca1発現を調節するための組成物及び方法
|
CA2873766A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating atp2a2 expression
|
WO2013173645A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating utrn expression
|
DK2850189T3
(en)
|
2012-05-16 |
2019-02-25 |
Translate Bio Ma Inc |
COMPOSITIONS AND PROCEDURES FOR MODULATING GENEPRESSION
|
SG11201407483YA
(en)
|
2012-05-16 |
2014-12-30 |
Rana Therapeutics Inc |
Compositions and methods for modulating smn gene family expression
|
EA201492116A1
(ru)
|
2012-05-16 |
2015-05-29 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии mecp2
|
WO2013173605A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating pten expression
|
EA201492121A1
(ru)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии семейства генов гемоглобина
|
WO2014025887A1
(en)
|
2012-08-07 |
2014-02-13 |
The General Hospital Corporation |
Selective reactivation of genes on the inactive x chromosome
|
EP2895200B1
(en)
|
2012-09-14 |
2019-11-06 |
Translate Bio MA, Inc. |
Multimeric oligonucleotide compounds
|
AU2013346767B2
(en)
|
2012-11-15 |
2019-04-11 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugates
|
CA2914536A1
(en)
|
2013-06-07 |
2014-12-11 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating foxp3 expression
|
WO2015035476A1
(en)
|
2013-09-16 |
2015-03-19 |
University Of Western Sydney |
Modulation of gene expression
|